175 related articles for article (PubMed ID: 30922608)
1. Cytokine release syndrome. Reviewing a new entity in the intensive care unit.
García Roche A; Díaz Lagares C; Élez E; Ferrer Roca R
Med Intensiva (Engl Ed); 2019 Nov; 43(8):480-488. PubMed ID: 30922608
[TBL] [Abstract][Full Text] [Related]
2. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
Freyer CW; Porter DL
J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
[TBL] [Abstract][Full Text] [Related]
3. CAR-T cell: Toxicities issues: Mechanisms and clinical management.
Wallet F; Sesques P; Devic P; Levrard M; Ader F; Friggeri A; Bachy E
Bull Cancer; 2021 Oct; 108(10S):S117-S127. PubMed ID: 34920794
[TBL] [Abstract][Full Text] [Related]
4. Management of cytokine release syndrome related to CAR-T cell therapy.
Chen H; Wang F; Zhang P; Zhang Y; Chen Y; Fan X; Cao X; Liu J; Yang Y; Wang B; Lei B; Gu L; Bai J; Wei L; Zhang R; Zhuang Q; Zhang W; Zhao W; He A
Front Med; 2019 Oct; 13(5):610-617. PubMed ID: 31571160
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T).
Alvi RM; Frigault MJ; Fradley MG; Jain MD; Mahmood SS; Awadalla M; Lee DH; Zlotoff DA; Zhang L; Drobni ZD; Hassan MZO; Bassily E; Rhea I; Ismail-Khan R; Mulligan CP; Banerji D; Lazaryan A; Shah BD; Rokicki A; Raje N; Chavez JC; Abramson J; Locke FL; Neilan TG
J Am Coll Cardiol; 2019 Dec; 74(25):3099-3108. PubMed ID: 31856966
[TBL] [Abstract][Full Text] [Related]
6. Cytokine Release Syndrome in the Pediatric Population and Implications for Intensive Care Management.
Romano J; Wilsterman E; Toal M; Joyce C
Crit Care Clin; 2023 Apr; 39(2):277-285. PubMed ID: 36898773
[TBL] [Abstract][Full Text] [Related]
7. [Management of cytokine release syndrome and macrophage activation syndrome following CAR-T cell therapy: Guidelines from the SFGM-TC].
Tudesq JJ; Yakoub-Agha M; Bay JO; Courbon C; Paul F; Picard M; Pochon C; Sterin A; Vicente C; Canet E; Yakoub-Agha I; Moreau AS
Bull Cancer; 2023 Feb; 110(2S):S116-S122. PubMed ID: 34895696
[TBL] [Abstract][Full Text] [Related]
8. Cytokine release syndrome in severe COVID-19.
Moore JB; June CH
Science; 2020 May; 368(6490):473-474. PubMed ID: 32303591
[No Abstract] [Full Text] [Related]
9. Management Principles Associated With Cytokine Release Syndrome.
Baer B; Dudley CV; Simons RM
Semin Oncol Nurs; 2019 Oct; 35(5):150931. PubMed ID: 31477411
[TBL] [Abstract][Full Text] [Related]
10. Extracorporeal cytokine removal in severe CAR-T cell associated cytokine release syndrome.
Stahl K; Schmidt BMW; Hoeper MM; Skripuletz T; Möhn N; Beutel G; Eder M; Welte T; Ganser A; Falk CS; Koenecke C; David S
J Crit Care; 2020 Jun; 57():124-129. PubMed ID: 32113143
[TBL] [Abstract][Full Text] [Related]
11. CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future Directions.
Hunter BD; Jacobson CA
J Natl Cancer Inst; 2019 Jul; 111(7):646-654. PubMed ID: 30753567
[TBL] [Abstract][Full Text] [Related]
12. [Management of cytokine release syndrome in adult and pediatric patients undergoing CAR-T cell therapy for hematological malignancies: Recommendation of the French Society of Bone Marrow and cellular Therapy (SFGM-TC)].
Yakoub-Agha I; Moreau AS; Ahmad I; Borel C; Hadhoum N; Masouridi-Levrat S; Naudin J; Nicolas-Virelizier E; Ouachée-Chardin M; Platon L; Quessar A; Roth-Guepin G; Beauvais D; Baruchel A; Cornillon J
Bull Cancer; 2019 Jan; 106(1S):S102-S109. PubMed ID: 30661749
[TBL] [Abstract][Full Text] [Related]
13. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.
Le RQ; Li L; Yuan W; Shord SS; Nie L; Habtemariam BA; Przepiorka D; Farrell AT; Pazdur R
Oncologist; 2018 Aug; 23(8):943-947. PubMed ID: 29622697
[TBL] [Abstract][Full Text] [Related]
14. Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes.
England JT; Abdulla A; Biggs CM; Lee AYY; Hay KA; Hoiland RL; Wellington CL; Sekhon M; Jamal S; Shojania K; Chen LYC
Blood Rev; 2021 Jan; 45():100707. PubMed ID: 32425294
[TBL] [Abstract][Full Text] [Related]
15. Critical Care Management of Chimeric Antigen Receptor T Cell-related Toxicity. Be Aware and Prepared.
Azoulay E; Shimabukuro-Vornhagen A; Darmon M; von Bergwelt-Baildon M
Am J Respir Crit Care Med; 2019 Jul; 200(1):20-23. PubMed ID: 30676776
[TBL] [Abstract][Full Text] [Related]
16. Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies.
Siegler EL; Kenderian SS
Front Immunol; 2020; 11():1973. PubMed ID: 32983132
[TBL] [Abstract][Full Text] [Related]
17. Bullous and Exanthematous Lesions Associated With Chimeric Antigen Receptor T-Cell Therapy in a Patient With Diffuse Large B-Cell Lymphoma.
Hu Y; Zheng W; Qiao J; Cui Q; Zhu Y; Chang AH; Huang H
JAMA Dermatol; 2020 Sep; 156(9):1026-1028. PubMed ID: 32432646
[No Abstract] [Full Text] [Related]
18. Cancer immunotherapy with CAR-T cells - behold the future.
Graham C; Hewitson R; Pagliuca A; Benjamin R
Clin Med (Lond); 2018 Aug; 18(4):324-328. PubMed ID: 30072559
[TBL] [Abstract][Full Text] [Related]
19. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells.
Norelli M; Camisa B; Barbiera G; Falcone L; Purevdorj A; Genua M; Sanvito F; Ponzoni M; Doglioni C; Cristofori P; Traversari C; Bordignon C; Ciceri F; Ostuni R; Bonini C; Casucci M; Bondanza A
Nat Med; 2018 Jun; 24(6):739-748. PubMed ID: 29808007
[TBL] [Abstract][Full Text] [Related]
20. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.
Kang S; Tanaka T; Inoue H; Ono C; Hashimoto S; Kioi Y; Matsumoto H; Matsuura H; Matsubara T; Shimizu K; Ogura H; Matsuura Y; Kishimoto T
Proc Natl Acad Sci U S A; 2020 Sep; 117(36):22351-22356. PubMed ID: 32826331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]